Compare GSK plc (GSK) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Marqeta Inc — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Marqeta Inc trades at $18.09 (market cap $1.82B). The key difference: GSK plc is far larger — about 50.5× Marqeta Inc's market cap, and GSK plc pays a 3.9% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Marqeta Inc for 44 Days on average.
| GSK | MQ | |
|---|---|---|
Market Cap | $91.88B | $1.82B |
Volume | 7,730,529 | 1,126,466 |
Sector | Health | Technology |
52-Week High | $61.18 | $20.32 |
52-Week Low | $43.24 | $15.04 |
Typical Hold Time | 93 Days | 44 Days |
Enterprise Value | $111.88B | $1.13B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Marqeta (MQ) trades at $18.11, up 6.15% with a bullish technical signal. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while revenue grew 23% year-over-year to $625M in 2025. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic expansion. However, valuation remains elevated with a P/E of 193.83 and negative EBITDA of -$19.27M despite improving cash flow trends.
Outlook remains mixed with analyst consensus at Hold (59% of ratings) and a $11.38 price target suggesting 37% downside. Key risks include contract renewals in Q3 2026 potentially slowing growth, while institutional sentiment is cautious despite technical strength. The stock's premium valuation requires sustained execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
